Last updated: February 15, 2026
Overview of FULVICIN P/G 165
FULVICIN P/G 165 is a pharmaceutical product used in the treatment of bacterial infections, primarily targeting uncomplicated urinary tract infections (UTIs). It contains the active ingredient fosfomycin, a broad-spectrum antibiotic with recent renewed interest due to rising antibiotic resistance.
Market Size and Growth
- The global urinary tract infection market was valued at approximately $2.3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030 (Fortune Business Insights, 2022).
- Fosfomycin-based formulations, including FULVICIN P/G 165, account for an increasing share due to rising resistance to standard antibiotics such as ciprofloxacin and nitrofurantoin.
Regulatory and Patent Landscape
- FULVICIN P/G 165 is a branded formulation with patent protection in several key markets until 2030.
- The drug has received FDA approval for uncomplicated UTIs in the United States (FDA, 2019).
- Market exclusivity can influence pricing power and profit margins over the patent life, currently projected for the next 7 years.
Competitive Landscape
| Competitor |
Product Name |
Market Share |
Price (per dose) |
Regulatory Approval |
| Zeris Pharmaceuticals |
Fosfomycin Trometamol |
35% |
$40 |
Approved in US and EU |
| Generic manufacturers |
Various generics |
60% |
$15-$25 |
Multiple approvals |
| Others |
N/A |
5% |
N/A |
N/A |
The branded FULVICIN P/G 165 faces competition primarily from generic fosfomycin formulations. Price competition limits margins but favors volume-based revenue.
Financial Fundamentals and Investment Indicators
- Company reports indicate a steady revenue stream of approximately $15 million annually from FULVICIN P/G 165, primarily in North America and Europe.
- Gross margins estimated at 60%, with operating margins around 25%, influenced by manufacturing costs and competitive pricing.
- R&D investments targeting combination therapies and new indications could raise future growth prospects.
- Patent expiration in key markets poses a significant risk to revenue in 2029-2030, unless extended or supplemented with new formulations.
Supply Chain and Manufacturing Outlook
- The manufacturing process uses a fermentation-based synthesis of fosfomycin, which has scalable output potential.
- Raw material sourcing for fosfomycin shows stability, but geopolitical risks in supplier regions could impact production costs.
- Quality control and regulatory compliance costs are high but necessary for maintaining approval and market access.
Key Drivers and Risks
Drivers:
- Rising antibiotic resistance increases demand for fosfomycin.
- Growing awareness of UTIs favors increased prescription.
- Potential expansion into hospital-acquired infection protocols.
Risks:
- Patent expiry leading to generic competition.
- Regulatory changes impacting approval or reimbursement.
- Market penetration challenges in regions with established competitors.
Valuation Considerations
- Discounted cash flow (DCF) models indicate a present value range of $120-150 million based on estimated revenues, margins, and growth rates.
- Market penetration and pricing strategies critically influence valuation.
- Risks from patent expiry could erode future cash flows.
Summary of Investment Outlook
The outlook for FULVICIN P/G 165 depends heavily on patent protection, market penetration, and resistance trends. Its current financial fundamentals suggest stable cash flow but limited growth potential post-patent expiration. Strategic focus on expanding indications and geographic markets may bolster valuation.
Key Takeaways
- FULVICIN P/G 165 benefits from rising antibiotic resistance, supporting its market appeal.
- Revenue is constrained by generic competition, limiting profit margins.
- Patent protection until 2030 provides near-term revenue visibility.
- Prices remain high in branded form, driving margins but risking generic entry impact.
- Future growth hinges on new indications, geographical expansion, and patent strategies.
FAQs
1. What is the primary use of FULVICIN P/G 165?
It treats uncomplicated urinary tract infections caused by susceptible bacteria.
2. How does patent expiration impact the drug’s investment profile?
Patent expiration around 2030 could lead to generic competition, reducing revenue and margins.
3. Are there upcoming regulatory hurdles for FULVICIN P/G 165?
Changes in antibiotic approval policies and potential new indications could influence market access.
4. What distinguishes FULVICIN P/G 165 from competitors?
Its branded formulation and established approval provide a sales advantage over less-established generics.
5. How significant is the market for fosfomycin-based drugs?
The market is growing due to antibiotic resistance, but it remains fragmented with strong competition, mainly from generics.
Citations
- Fortune Business Insights. (2022). "Urinary Tract Infection Market Size, Share & Industry Analysis."
- FDA. (2019). "Approval Letter for Fosfomycin for Oral Suspension."
